The efficacy of oral etoricoxib in pain control during colposcopy-directed cervical biopsy: A randomized control trial
Phase 4
- Conditions
- Abnormal cervical screening result in patients with indication for colposcopy with directed biopsy and endocervical curettagecolposcopy with directed biopsy and endocervical curettageoral etoricoxibpain score
- Registration Number
- TCTR20220712004
- Lead Sponsor
- /A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- Female
- Target Recruitment
- 110
Inclusion Criteria
abnormal cervical screening result that indication for colposcopy according to ASCCP2019
1.ASC-US
2.ASC-H
3.AGC NOS
4.LSIL
5.HSIL
6.SCC
7.HPV16/18 infection
Exclusion Criteria
1.NSAIDs allergy
2.pregnancy or breast feeding
3.history of pain killer 24 hours prior to colposcopy
4.contraindication for etoricoxib as below
gastric ulcer or upper gastrointestinal bleeding
severe hepatic disease (serum albumin <25ng/l)
severe renal disease (CrCl <30 ml/min)
inflammatory bowel disease
heart failure
blood pressure more than 140/90 mmHg
coronary artery disease, peripheral arterial disease
stroke
history of thrombolytic drug, oral contraceptive pill
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pain score before colposcopy, speculum insertion, acetic acid apply, cervical biopsy, endocervical curettage, post colposcopy 10 mins, post colposcopy 24 hours Numerical rating scale
- Secondary Outcome Measures
Name Time Method adverse event after etoricoxib 30 mins - 24 hours Patient reported outcome using a questionnaire interview